Atreca Inc Stock Fundamentals
| BCELDelisted Stock | USD 1.04 0.02 1.89% |
Atreca Inc fundamentals help investors to digest information that contributes to Atreca's financial success or failures. It also enables traders to predict the movement of Atreca Pink Sheet. The fundamental analysis module provides a way to measure Atreca's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Atreca pink sheet.
Atreca |
Atreca Inc Company Shares Outstanding Analysis
Atreca's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Atreca Shares Outstanding | 38.41 M |
Most of Atreca's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Atreca Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, Atreca Inc has 38.41 M of shares currently outstending. This is 78.72% lower than that of the Biotechnology sector and 64.05% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 93.28% higher than that of the company.
Atreca Inc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Atreca's current stock value. Our valuation model uses many indicators to compare Atreca value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Atreca competition to find correlations between indicators driving Atreca's intrinsic value. More Info.Atreca Inc is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Atreca's earnings, one of the primary drivers of an investment's value.Atreca Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Atreca's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Atreca could also be used in its relative valuation, which is a method of valuing Atreca by comparing valuation metrics of similar companies.Atreca is currently under evaluation in shares outstanding category among its peers.
Atreca Fundamentals
| Return On Equity | -1.83 | |||
| Return On Asset | -0.51 | |||
| Current Valuation | (17.08 M) | |||
| Shares Outstanding | 38.41 M | |||
| Shares Owned By Insiders | 2.73 % | |||
| Shares Owned By Institutions | 24.54 % | |||
| Number Of Shares Shorted | 272.73 K | |||
| Price To Earning | (3.53) X | |||
| Price To Book | 0.28 X | |||
| EBITDA | (76.42 M) | |||
| Net Income | (97.76 M) | |||
| Cash And Equivalents | 101.73 M | |||
| Cash Per Share | 2.64 X | |||
| Total Debt | 63.88 M | |||
| Debt To Equity | 0.57 % | |||
| Current Ratio | 8.14 X | |||
| Book Value Per Share | 0.27 X | |||
| Cash Flow From Operations | (65.08 M) | |||
| Short Ratio | 0.16 X | |||
| Earnings Per Share | (2.50) X | |||
| Target Price | 5.5 | |||
| Number Of Employees | 90 | |||
| Beta | 1.17 | |||
| Market Capitalization | 3.02 M | |||
| Total Asset | 155.03 M | |||
| Retained Earnings | (456.92 M) | |||
| Working Capital | 61.73 M | |||
| Current Asset | 60.02 M | |||
| Current Liabilities | 3.56 M | |||
| Z Score | -5.25 | |||
| Net Asset | 155.03 M |
About Atreca Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Atreca Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atreca using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atreca Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California. Atreca Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Atreca Pink Sheet
If you are still planning to invest in Atreca Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Atreca's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Stocks Directory Find actively traded stocks across global markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |